Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Radiopharm Theranostics Limited Sponsored ADR ( (RADX) ) has shared an update.
Radiopharm Theranostics, a clinical-stage radiopharmaceutical company listed on the ASX and Nasdaq, focuses on innovative radiotherapeutics for cancer diagnosis and treatment in high unmet-need indications. Its pipeline spans peptides, small molecules and monoclonal antibodies in solid tumors, with one Phase 2 and four Phase 1 trials underway across lung, breast, prostate and brain metastases.
On March 27, 2026, Radiopharm reported dosing the first patient in its first-in-human Phase 1 clinical trial of RAD 402, an anti-KLK3 monoclonal antibody radiolabelled with Terbium 161 for advanced prostate cancer. The dose-escalation study will evaluate safety, tolerability, distribution and early activity, informed by preclinical data showing strong tumor targeting with minimal bone and marrow uptake, and the company expects to share initial data from the first two dose levels in the second half of 2026, marking a key milestone in its prostate cancer program and broader theranostics pipeline.
RAD 402’s targeting of KLK3, the gene encoding Prostate Specific Antigen and highly expressed in prostate tumors and metastases, underscores Radiopharm’s push toward more selective radiotherapies. The trial’s progress will be closely watched by stakeholders as it may validate a differentiated, first-in-class approach that could enhance the company’s position in the competitive radiopharmaceutical oncology field if early safety and activity signals are favorable.
The most recent analyst rating on (RADX) stock is a Sell with a $4.00 price target. To see the full list of analyst forecasts on Radiopharm Theranostics Limited Sponsored ADR stock, see the RADX Stock Forecast page.
Spark’s Take on RADX Stock
According to Spark, TipRanks’ AI Analyst, RADX is a Neutral.
The score is held down primarily by persistent losses and ongoing cash burn, despite a debt-free balance sheet. Technical indicators also remain bearish with the stock trading below key moving averages and a negative MACD. Valuation support is limited because the company is unprofitable (negative P/E) and offers no dividend yield.
To see Spark’s full report on RADX stock, click here.
More about Radiopharm Theranostics Limited Sponsored ADR
Radiopharm Theranostics Limited is a clinical-stage radiotherapeutics company developing radiopharmaceutical products for diagnostic and therapeutic use in oncology, targeting areas of high unmet medical need. Listed on the ASX and Nasdaq, it is advancing a pipeline of peptide, small-molecule and monoclonal antibody platforms across solid tumors including lung, breast, prostate and brain metastases through multiple Phase 1 and Phase 2 trials.
The company’s strategy centers on innovative targeted radiotherapies that leverage precise tumor biomarkers, such as KLK3 in prostate cancer, to improve efficacy and limit off-target toxicity. By progressing several first-in-class candidates in early clinical development, Radiopharm aims to strengthen its position in the fast-growing theranostics market and appeal to investors focused on next-generation oncology treatments.
Average Trading Volume: 168,078
Technical Sentiment Signal: Sell
Current Market Cap: $48.83M
For a thorough assessment of RADX stock, go to TipRanks’ Stock Analysis page.